Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)
104.97 x 5 105.12 x 2
Post-market by (Cboe BZX)
104.97 +0.35 (+0.33%) 04/17/25 [NASDAQ]
104.97 x 5 105.12 x 2
Post-market 104.97 unch (unch) 16:07 ET
Profile for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Ligand Pharm 555 HERITAGE DRIVE SUITE 200 JUPITER FL 33458 USA

www.ligand.com Employees: 68 P: 858-550-7500

Sector:

Medical

Description:

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.

Key Statistics

Overview:

Market Capitalization, $K 2,014,457
Enterprise Value, $K 1,942,147
Shares Outstanding, K 19,255
Annual Sales, $ 167,130 K
Annual Net Income, $ -4,030 K
Last Quarter Sales, $ 42,810 K
Last Quarter Net Income, $ -31,090 K
EBIT, $ 10,350 K
EBITDA, $ 44,740 K
60-Month Beta 1.07
% of Insider Shareholders 5.90%
% of Institutional Shareholders 91.28%
Float, K 18,119
% Float 94.10%
Short Volume Ratio 0.69

Growth:

1-Year Return 33.09%
3-Year Return 7.92%
5-Year Return 7.52%
5-Year Revenue Growth 38.95%
5-Year Earnings Growth -110.43%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.64 on 02/27/25
Next Earnings Date 05/06/25 [--]
Earnings Per Share ttm -0.31
EPS Growth vs. Prev Qtr -320.51%
EPS Growth vs. Prev Year -307.59%
Annual Dividend Yield 0.00%
Most Recent Dividend 2.500 on 04/03/07
Dividend Payable Date 07/01/10
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 11/19/10

LGND Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 37.91
Price/Earnings to Growth N/A
Return-on-Equity % -0.81%
Return-on-Assets % -0.72%
Profit Margin % -2.41%
Debt/Equity 0.00
Price/Sales 12.30
Price/Cash Flow 66.47
Price/Book 2.43
Book Value/Share 43.94
Interest Coverage -1.83
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro